keyboard_arrow_right
Search & Filter keyboard_arrow_right
keyboard_arrow_left Hide
Main Conference Day 2 - CET/CEST (Cent Europe Summer, GMT+2)
keyboard_arrow_leftSearch & Filter
search
Streams
Formats
Main Conference Day 2 - CET/CEST (Cent Europe Summer, GMT+2)
search
Streams
Formats
07:15 - 07:4025 mins
Registration, Coffee and Exhibit/Poster Viewing
07:40 - 08:1030 mins
MORNING SCIENTIFIC BRIEFING: Manufacturing Next-Generation Multi Domain Protein Pharmaceuticals Using the Leap-In Transposase® Platform
- Claes Gustafsson, PhD - Co-Founder & CCO, ATUM
08:15 - 08:205 mins
Beyond Antibodies: New Developments for Therapy, Diagnostics and Research
Chairman’s Remarks
- Andreas Plückthun, PhD - Professor and Director, University of Zurich
08:15 - 08:205 mins
Strategies for Improving the Therapeutic Window of Antibody Drugs
Chairwoman’s Remarks
- Kerry Chester, PhD - Professor of Molecular Medicine, UCL Cancer Institute
08:20 - 08:5030 mins
Beyond Antibodies: New Developments for Therapy, Diagnostics and Research
Modular Binding of Linear Epitopes
- Andreas Plückthun, PhD - Professor and Director, University of Zurich
08:20 - 08:5030 mins
Strategies for Improving the Therapeutic Window of Antibody Drugs
OPS-γδ: Opsonin Delivery from an Allogeneic Cell Therapy Platform
- Jonathan Fisher, Ph.D. - NIHR Clinical Lecturer & GOSHC Springboard Fellow, UCL-GOS Institute of Child Health
08:50 - 09:2030 mins
Beyond Antibodies: New Developments for Therapy, Diagnostics and Research
Ensovibep, A SARS-CoV-2 Pan-variant Neutralizing DARPin Therapeutic
- Daniel Steiner, Ph.D. - SVP, Oncology Research, Molecular Partners
08:50 - 09:2030 mins
Strategies for Improving the Therapeutic Window of Antibody Drugs
XTENylated Protease Activated T Cell Engagers: XPATS - A Novel Format to Mitigate the On-target, Off-tumor Problem
- Tracy Young, PhD - Director, Protein Engineering, Amunix Pharmaceuticals
09:20 - 09:5030 mins
Beyond Antibodies: New Developments for Therapy, Diagnostics and Research
Ubiquibodies: The Next Generation of Targeted Protein Degraders
- Matthew DeLisa, Ph.D. - William L. Lewis Professor of Engineering, Cornell University
09:20 - 09:5030 mins
Strategies for Improving the Therapeutic Window of Antibody Drugs
New Developments with Conditionally Activated Tetravalent Bispecific Antibodies
- Neil Brewis, Ph.D. - Chief Scientific Officer, F-star Therapeutics
09:50 - 10:2030 mins
Networking Refreshment Break and Exhibit/Poster Viewing
Concurrent Streams
10:20 - 10:5030 mins
Beyond Antibodies: New Developments for Therapy, Diagnostics and Research
Pushing the Envelope of Synthetic Binding Proteins with Monobodies
- Shohei Koide, PhD - Professor of Biologics Design, Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine
10:20 - 10:5030 mins
Strategies for Improving the Therapeutic Window of Antibody Drugs
Peripheral and Tumoral Immune Activity in the Expansion Part of the First-in-Human DuoBody®-PD-L1x4-1BB (GEN1046) Trial
- Nora Pencheva, Ph.D. - Associate Director, Translational Medicine Lead, Genmab B.V.
10:50 - 11:2030 mins
Beyond Antibodies: New Developments for Therapy, Diagnostics and Research
Radionuclide Molecular Targeting of Cancer Using Engineered Scaffold Proteins
- Vladimir Tolmachev, Ph.D. - Professor, Department of Immunology, Genetics, Uppsala University
10:50 - 11:2030 mins
Strategies for Improving the Therapeutic Window of Antibody Drugs
A Triple-targeting DARPin T-cell Engager Approach to Improve Safety and Efficacy for the Treatment of AML
- Christian Reichen, Ph.D. - Associate Director Oncology Research, Molecular Partners AG
11:20 - 11:5030 mins
Beyond Antibodies: New Developments for Therapy, Diagnostics and Research
Generation of Antibody-like Modulators of Ion Channels by Fusing Cysteine Rich Miniproteins into Peripheral CDR Loops
- Aneesh Karatt-Vellatt, PhD - Chief Scientific Officer, Maxion Therapeutics
11:20 - 11:5030 mins
Strategies for Improving the Therapeutic Window of Antibody Drugs
Bringing Amanitin to the Clinic - Engineering a Therapeutic Window into a Poison
- George Badescu, PhD - Chief Business Officer, Heidelberg Pharma
Scientific Briefings
11:50 - 12:5060 mins
Scientific Briefing 1
Applications of the Retrogenix Cell Microarray Technology for IND-enabling Specificity Screening
- Diogo Rodrigues Ferreirinha - European Senior Account Manager, Charles River Laboratories
11:50 - 12:2030 mins
Scientific Briefing 2
Engineering Human Antibodies Discovered with AlivaMab Mouse into a Dual-Antagonist Bispecific Antibody Therapeutic
- Jonah Rainey, PhD - VP of Antibody Engineering and Protein Science, AlivaMab Discovery Services
12:20 - 12:5030 mins
Scientific Briefing 2
EVOiR&D: An Integrated Discovery and Development Platform to Deliver Best-in-class Biologics at Evotec
- Thierry Wurch, PhD - Senior VP, Integrated Biologics Discovery, EVOTEC (France) SAS
12:50 - 13:5060 mins
Networking Luncheon and Exhibit/Poster Viewing
Scientific Briefings
13:50 - 14:2030 mins
Scientific Briefing 1
Accelerating High Throughput Antibody Purification Using Dual Flow Chromatography
- Vincent Batori, PhD - Application Specialist Biomolecules Europe, Biotage AB
13:50 - 14:2030 mins
Scientific Briefing 2
Tracking Antibody Enrichment in Display Libraries with the IGX Platform
- Lorenzo Fanchi - Team Lead Product Management, ENPICOM
14:20 - 14:255 mins
Non-cancer Applications of Therapeutic Antibodies
Chairman’s Remarks
- Hans de Haard, PhD - Chief Scientific Officer, Argenx
14:20 - 14:255 mins
T-Cell Engagers and Beyond
Chairwoman’s Remarks
- Janine Schuurman, Ph.D. - Corporate VP Research and Innovation, Genmab
14:25 - 14:5530 mins
Non-cancer Applications of Therapeutic Antibodies
A New Treatment Concept in Pemphigus Therapy: Long Term Response to Rituximab
- Sebastien Calbo, PhD - Research Scientist, Normandie University Rouen
14:25 - 14:5530 mins
T-Cell Engagers and Beyond
CD3-bispecific Antibody Therapy is Effective in Solid Tumors after Increased T cell Infiltration Induced by Vaccines
- Jim Middelburg - .., Leiden University Medical Center
14:55 - 15:2530 mins
Non-cancer Applications of Therapeutic Antibodies
Mastering Fibrosis Resolution and Tissue Regeneration by HGF-mimetic Antibodies
- Paolo Michieli, PhD - Chief Scientific Officer, AgomAb Therapeutics
14:55 - 15:2530 mins
T-Cell Engagers and Beyond
Engineered Immunocompetent Models of the Human Intestine: Applications in TCB Safety Profiling and Beyond
- Nikolche Gjorevski - Principal Scientist and Lead, Roche
15:25 - 15:5530 mins
Non-cancer Applications of Therapeutic Antibodies
Data from the ADAPT Phase 3 Study of Efgartigimod in Generalized Myasthenia Graves Patients
- James Howard Jr., MD - Professor of Neurology, Medicine and Allied Health, UNC Chapel Hill
15:25 - 15:5530 mins
T-Cell Engagers and Beyond
A Novel Multivalent T-cell Engaging Bispecific Antibody for Selective Killing of Solid Tumor Cells
- Brian Avanzino, Ph.D. - Scientist III, Discovery, Amgen
15:55 - 16:2530 mins
Networking Refreshment Break and Exhibit/Poster Viewing
16:25 - 16:5530 mins
Non-cancer Applications of Therapeutic Antibodies
Human Antibody Repertoires are Simple, Unique, and Dynamic
- Albert Bondt, PhD - Senior Scientist, Utrecht University
16:25 - 16:5530 mins
T-Cell Engagers and Beyond
Developing Protease-Activated T Cell Engager Prodrugs with Improved Spatial and Temporal Controls
- Jack Lin, Ph.D. - Senior Director, New Technologies, Harpoon Therapeutics
16:55 - 17:2530 mins
Non-cancer Applications of Therapeutic Antibodies
RNA-Engineered Cell Therapies for Autoimmune Disease
- Michael Singer, MD, PhD - Co-Founder, CSO and Director, Cartesian Therapeutics
16:55 - 17:2530 mins
T-Cell Engagers and Beyond
The Gammabody Platform: Novel Bispecific Gamma-delta T Cell Engagers for the Treatment of Prostate Cancer
- Paul Parren, PhD - EVP, Head of R&D, Lava Therapeutics
17:25 - 17:5530 mins
Non-cancer Applications of Therapeutic Antibodies
A Therapeutic Antibody to ApoC3 for Treatment of Hypertriglyceridemia
- Daniel Rader, MD - Seymour Gray Professor of Molecular Medicine, Perelman School of Medicine, University of Pennsylvania
17:25 - 17:5530 mins
T-Cell Engagers and Beyond
In Vitro and In Vivo Studies Establish DuoBody®-CD3xB7H4 As a Novel Drug Candidate for the Treatment of Solid Cancers
- Louise Koopman, PhD - Scientific Project Lead, Translational Research, Genmab
17:55 - 18:005 mins
Close of Conference
Get the latest news.
As it happens
Sign up to get the latest on the agenda and speakers.
Filter
Streams
Formats